New three-year real-world data on Leqembi® presented at CTAD 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioArctic (BIOA B) partner Eisai presented new real-world results for Leqembi in early Alzheimer’s disease at the CTAD conference. The LEADER analysis included 560 patients at 13 U.S. sites. In a prespecified comparison of 504 treated patients with 573 patients in a weighted external group, the treated group had a 76% lower rate of progression to moderate or severe Alzheimer’s dementia through 36 months.
Among 546 assessable patients, 81.1% remained stable or improved after about 18 months on average. A separate exploratory analysis of approximately 5,000 Leqembi patients found a 12.4% pooled rate of amyloid-related imaging abnormalities (ARIA), compared with 21.5% in the Phase 3 Clarity AD trial. The real-world analyses were not placebo-controlled; differences between patient groups may affect the comparisons.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointLeqembi progression rate was 76% lower through 36 months versus a weighted external group in a prespecified comparison.
- Minor pointDisease stage was stable or improved in 81.1% of 546 assessable patients after approximately 18 months on average.
- Minor point. Forward-looking: it has not happened yet and may not happen.Three-year modeling estimated that 95.0% of the 560 treated patients would remain in early-stage Alzheimer’s disease.
- Minor pointPooled ARIA rate was 12.4% across 16 real-world cohorts, versus 21.5% in the Phase 3 Clarity AD trial.
- Minor pointSymptomatic ARIA was reported in 0.8% in the pooled real-world analysis, versus 2.8% in Clarity AD.
9 minor points
- Minor pointPooled brain swelling or fluid buildup (ARIA-E) occurred in 4.0%, versus 12.6% in Clarity AD.
- Minor pointPooled bleeding-related imaging changes (ARIA-H) occurred in 9.4%, versus 17.3% in Clarity AD.
- Minor pointTreatment persistence was 87.5% at chart review among 560 patients, with approximately 19 months of treatment on average.
- Minor pointPersistence after reaching 18 months was 91.7% among patients who reached that treatment milestone.
- Minor pointAmyloid scans turned negative in 77% of 43 patients with paired scans at a median follow-up of 18.1 months.
- Minor pointMonthly intravenous maintenance had 218 transitions; 71.1% of recipients remained stable at an average of 26 months from treatment initiation.
- Minor pointWeekly under-the-skin maintenance had 64 transitions; 76.6% of recipients remained stable at an average of 25.1 months from treatment initiation.
- Minor pointWeekly under-the-skin maintenance persistence was 64 of 64 patients at chart review.
- Minor pointUnder-the-skin maintenance safety showed no reported ARIA or other notable safety events during the maintenance period.
Negative
- Minor pointRetrospective evidence lacked placebo-controlled groups and can be affected by bias, missing or inconsistent data, and other factors.
- Minor pointLEADER imaging abnormalities included ARIA-E in 6.6% versus 6.3% in ALZ-NET and ARIA-H in 11.1% versus 10.1%.
- Minor pointAdverse events led to a 3.2% treatment discontinuation rate in the exploratory real-world analysis.
- Minor pointIntravenous maintenance had a 0.5% rate of isolated ARIA-H during the maintenance period.
Key Figures
- Study population
- 560 patients
- LEADER real-world analysis across 13 US clinical sites
- Lower progression rate
- 76% lower rate (HR 0.24; 95% CI, 0.15–0.39)
- Progression to moderate or severe Alzheimer's dementia through 36 months versus an ADNI-weighted external control cohort
- Stable or improved
- 81.1% of 546 patients
- After an average of approximately 18 months of treatment
- Remained on treatment
- 87.5% of 560 patients
- At chart extraction; average treatment duration was approximately 19 months
- Estimated to remain in early disease stages
- 95.0%
- Through three years of treatment, based on statistical modeling of observed real-world data
- Became amyloid-negative
- 77% (33 of 43 patients)
- Among patients with baseline and follow-up amyloid PET scans; median follow-up of 18.1 months
- Pooled total ARIA rate
- 12.4% versus 21.5%
- Across 16 real-world studies versus the Phase 3 Clarity AD study
Key Terms
amyloid pet medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The data were presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in
LEADER study key findings
LEADER patients showed slower progression compared to ADNI control[2]:
- In a pre-specified comparison of patients in LEADER (N=504) with an ADNI-weighted external control cohort (N=573), patients treated with Leqembi had a
76% lower rate of progression to moderate or severe Alzheimer's disease dementia through 36 months (HR 0.24;95% CI, 0.15–0.39).
More than 8 in 10 patients remained stable or improved[3]:
- Among 546 patients whose change in disease stage could be assessed after an average of approximately 18 months of treatment,
81.1% were reported as stable or improved compared with baseline. Of these patients,75.8% remained stable and5.3% improved. - Results were generally consistent across groups defined by sex, race, ethnicity, APOE genotype and concomitant antithrombotic use.
- At the time of chart extraction,
87.5% of the 560 patients remained on Leqembi treatment, with an average treatment duration of approximately 19 months.
Most patients estimated to remain in early Alzheimer's disease:
- Among all 560 patients in the study,
95.0% were estimated to remain in the early stages of Alzheimer's disease through three years of treatment, based on statistical modeling of observed real-world patient data.
New real-world evidence shows amyloid clearance:
- Among 43 patients across six sites performing both baseline and follow-up amyloid PET scans,
77% (33) became amyloid-negative at a median follow-up of 18.1 months. (IQR 16.4–18.7 months).
Expanding experience with Leqembi maintenance therapy:
- Of the patients who reached 18 months of treatment,
91.7% remained on Leqembi. A total of 218 patients transitioned to intravenous (IV) maintenance treatment once-every-four-weeks., Following approval of once-weekly subcutaneous (SC) maintenance treatment, 64 patients transitioned to that regimen. - Among patients receiving monthly IV maintenance treatment,
71.1% remained stable after an average of 26 months from treatment initiation. Among patients receiving weekly SC maintenance treatment,76.6% remained stable after an average of 25.1 months. - All 64 patients receiving SC maintenance treatment remained on therapy at the time of chart extraction.
- No ARIA[4] events were reported during the subcutaneous maintenance period, and there were no other safety events of significance. Isolated ARIA-H was reported in
0.5% of patients during the IV maintenance period.
Clinical outcomes consistent between women and men
79.3% of women (N=300) and83.3% of men (N=246) in the study were reported as stable or improved3.
- Treatment duration and persistence were similar across sexes, with
86.0% of females and88.9% of males remaining on therapy at time of chart extraction. - ARIA incidence and severity were generally consistent between female and male patients: any ARIA (
14.7% females vs.17.0% males), ARIA-E (7.5% females vs.5.5% males), ARIA-H (9.8% females vs.12.6% males), isolated ARIA-H (7.2% females vs.11.5% males).
Safety findings consistent with other real-world experience:
Overall safety findings in LEADER were consistent with the independent ALZ-NET registry and the US prescribing information for Leqembi.
- ALZ-NET is a North American voluntary health care provider-enrolled patient network that collects longitudinal clinical, imaging, and safety data in patients treated with FDA-approved AD therapies. Over 1,700 patients taking Leqembi were included in ALZ-NET at the time of data extraction.
- ARIA-E was observed in
6.6% of patients in LEADER compared with6.3% in ALZ-NET, while ARIA-H was observed in11.1% and10.1% of patients, respectively. - Observed ARIA rates were generally consistent regardless of APOE ε4 status, concomitant antithrombotic use, race and ethnicity.
Additional real-world analysis of approximately 5,000 patients[5]:
A separate post hoc exploratory analysis presented at CTAD evaluated 16 published real-world Leqembi cohorts across six countries, representing approximately 5,000 patients treated in routine clinical practice.
- Across the 16 studies, the pooled total ARIA rate was
12.4% , compared with21.5% in the Phase 3 Clarity AD study. ARIA-E occurred in4.0% compared with12.6% in Clarity AD, while ARIA-H occurred in9.4% compared with17.3% . - Symptomatic ARIA was reported in
0.8% compared with2.8% in Clarity AD. - Treatment discontinuation due to adverse events was
3.2% .
Limitations of Real-World Studies
Retrospective real-world studies can be valuable in providing additional information to complement clinical trial data; however, there are potential limitations to consider, including: potential for biases, data completeness and consistency, lack of a control group, interpretation of data due to lack of placebo-controlled arms, and confounding variables, and data inconsistency. Data inconsistency may be mitigated by providing site access to standardized electronic case-report forms.
The information was released for public disclosure, through the agency of the contact person below, on November 18, 2026, at 5.15 pm CET.
For further information, please contact:
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180
Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08
About Leqembi® (lecanemab)
Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
Leqembi is approved in 53 countries and is under regulatory review in six countries and regions. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in nine countries and regions, including the US,
Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease has been ongoing since July 2020. These individuals are clinically normal and have intermediate or elevated levels of amyloid in their brains. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in
About the collaboration between BioArctic and Eisai
BioArctic has a long-term collaboration with Eisai since 2005 regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed in 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed in 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport therapies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
[1] The three-year LEADER Study is a multicenter, retrospective real-world study designed to examine LEQEMBI utilization, treatment persistence, transition to maintenance therapy, safety, cognitive and functional assessments, and healthcare professional (HCP) implementation learnings in diverse U.S. clinical settings for patients with early AD. The study integrated deidentified chart and electronic medical record (EMR) data from 13 U.S. sites, HCP surveys and HCP interviews. This updated analysis included 560 patients with early AD who, as of September 2026, received at least seven LEQEMBI initiation infusions. The maintenance therapy analysis included patients who received biweekly IV initiation treatment for 18 months, followed by at least three months of IV or SC maintenance therapy.
[2] ADNI is a clinical research project launched in 2005 to develop methods to predict the onset and progression of AD and to confirm the effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well as patients with mild cognitive impairment (MCI) and early stages of AD.
[3] Change in clinical disease stage was defined as:
- Stable: Patient remaining in the same clinical disease stage (MCI due to AD or mild AD dementia) from baseline throughout the course of LEQEMBI treatment.
- Improvement: Patient transitioning from mild AD dementia at baseline to MCI due to AD over the course of LEQEMBI treatment.
- Progression: Patient advancing from MCI at baseline to mild/moderate AD dementia or from mild AD dementia at baseline to moderate AD dementia throughout the course of LEQEMBI treatment.
[4] ARIA refers to amyloid-related imaging abnormalities that can be observed with anti-amyloid beta antibody treatment and includes ARIA-E, which involves edema/effusion, and ARIA-H, which involves hemosiderin deposition, including cerebral microhemorrhage, cerebral macrohemorrhage and superficial siderosis, as observed on brain magnetic resonance imaging (MRI).
[5] The meta-analysis on ARIA rates and safety profiles in clinical practice included centers located in the U.S., China, South Korea, Japan, Italy and Israel. Patients were treated between 2023 and 2026 and received at least six months of LEQEMBI treatment.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
New three-year real-world data on Leqembi® presented at CTAD 2026 |
View original content:https://www.prnewswire.com/news-releases/new-three-year-real-world-data-on-leqembi-presented-at-ctad-2026-302944135.html
SOURCE BioArctic
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.